A Phase 3 Randomized Double- Or Observer-Blinded Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a Respiratory Syncytial Versus (RSV) Prefusion F Subunit Vaccine in Infants Born To Women Vaccinated During Pregnancy

Brief description of study

The purpose of this study is to find out if Pfizer’s investigational RSVpreF vaccine prevents the development of RSV illness in your baby. A new investigational vaccine is one that is not approved for sale in this country. This study will explore whether giving the study vaccine, Respiratory Syncytial Virus vaccine (RSVpreF for short) may help protect babies against RSV infection. The safety of RSVpreF will also be assessed. This study is different from your and your baby’s regular medical care. The purpose of regular medical care is to improve or otherwise manage your and your baby’s health, but the purpose of research is to gather information to advance science and medicine and does not replace your or your baby’s regular medical care


Clinical Study Identifier: s20-00068
ClinicalTrials.gov Identifier: NCT04424316
Principal Investigator: Leonard R Krilov.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.